Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what you need to know. Insulet beat anal...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that genera...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?
Shareholders of Insulet would probably like to forget the past six months even happened. The stock dropped 54.4% and now trades at $144.10. This might have i...
